#RPG#rpglife life science business analysis,
It's was my diwali pick trying make two cent to add some value
A turnaround company with margins expansion & get rid off from DPCO specially your monopoly product ✨🧵
1/n 👉Leader in immunosuppressant segment
👉50+ year rich legacy, integrated operation with capabilities of both development & mfg in API & formulation,
👉company operating in domestic & international mkts in branded formulation,
👉global generic, API🧬💊
2/n 👉6 text book brand are trusted by doctor and patient
👉3 mfg units
👉1100+ permanent employee
👉50+ countries presence,
👉Enduring relationship with leading generic players of World 🌍
3/n Company is almost debt free, good profit growth of 29% CAGR last 5 years, healthy dividend paying
65% boz comes from domestic formulation
19% biz comes from international formulation
16% biz comes from API,
all segments growth is really good
4/n 👉Yugal sikri sir joined in oct18.
👉Rajat Bhargava joined in Jan21.
What make company turnaround,Management change
When in India in domestic cut throat competition,when your moated product is in dpco category
Raw material price hike but you cant making price hike dueto DPCO
5/n All products list
6/n 👉Naprosyn
Used in jointpain, headache, some cases in fever also.
👉Naprosyn D especially used in migraine
👉Naxdom sun Pharma is mkt leader
👉Napra D (intas) vgood brand
7/n
now my scuttlebutt comes,
63 rs of MRP of 15 tab product comes in DPCO
Almost 4 rs per tab
8/n Now added sodium in product,
Coming rid of dpco now company got pricing power,
its almost 80 rs of 10 tab means 8 rs tab
10/n At present 87 rs per 10 tab packing, Company want this brand 100 crore in future( scuttlebutt)
11/n 👉Azoran
Immunosuppresants mainly used in transplant
👉Aldactone specially used as diuretics ( potassium sparing) in heart failure,blood pressure, oedema ,removing excess salt & water from body.
👉Lomotil treatment for diarrhoea
👉Serenace treatment for psychosis,mania😴
12/n 👉Romilast BL uses for anti allergic condition sneezing 🤧
👉Tricaine almagel used for heartburn🔥
👉T jaki uses in moderate to severe joint pain
👉Gliptin mainly used in TYPE 2 DIABETES,
I covered uses only but all drug had side effects also,don't take any medicine direct
13/n 👉84000/- Doctor👨⚕️🩺 Q2fy23,
👉500 MR TODAY APPROX,
👉20% covering speciality division
👉80% covering mass division
👉MR PRODUCTIVITY IS ALMOST 5.5 LALH from 3.5 LAKH
14/n Revenue not so much increase but pat margins is expanded see after 2018
15/n Promoter increased stake
16/n 👉Thesis
Margin expansion of main moated product, step by step increase their portfolio,
MR productivity is good.
👉Anti thesis
Political instability in Myanmar,
Margin expansion almost done now work on growth also, frequent change in management in past track
17/n 👉Credit rating ICRA
LONG TERM 35 cr A STABLE.
LONG TERM FUND BASED 40 CR A STABLE.
SHORT TERM 25 CR A1
👉Must read all concall company recent give me answer who steal the show in asking questions 🫡
18/n 👉On valuation part no so expert imho fairly priced
MKT CAP - 1470/-
Cmp - 890/-
P/E- 24.
ROCE -31 %
ROE - 21%
Debt free with high promoter holding,
👉Sources
concall ,investor presentation, AR, LinkedIn, scuttlebutt, screener,valuepicker.
👉DPCO - Drug price control org.
19 / n
If like this thread pls LIKE & RT,
Not so good analyst, definitely something missed , always learner 🙏
Thread ends 🧵🧵🧵
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Second wave of COVID 19 impacted lives ,bussiness across the board.
We have also started to see inflation across economic in the world, interest rate increase & with ukrarian war conflict,supply chain constraints.
2/n Even the world experienced chaos and disruption, we delivered our highest growth .
FY22 revenues grew by 58% to 183.84 crores while consolidated EBITDA grew by 72% to Rs 43.5 crore from 25.24 compared with the year ago period. EBITDA margins expanded to 23.6 % from 21.7%
3/n Net profit too increased by 112% to Rs 24.8crores from Rs 11.7 crores compared with the same period a year ago. #betadrugs commands a strong position in the Indian market with more than 112 SKUs and its products are available across all major Corporate & Govt hospitals.
Gufic bio science stock analysis
( RT if beneficial)
A Thread 🧵🧵👇
1/n Company analysis
Mkt cap 2280( 18/03/2022)
CMP 235
P/E 25
ROCE 29%
ROE -29%
PROMOTER HOLDING 65% TO 75%
DEBT TO EQUITY ALMOST NIL
2/n gufic is engaged in r&d, mfg, mkt,distribution & sale of pharma & allied products,3rd fastest growing among the 100 pharma in india,largest mfg of lyophilized injection in india & fully automated,therapy areas like antibiotic,antifungal,cardiac, infertilty,antiviral, ppi.